Larimar Therapeutics (LRMR) presented data from the company’s Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp in Friedreich’s ataxia, or FA, at the International Congress for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback